What have we learnt from Vioxx?
Krumholz
Harlan M
HM
Department of Medicine, Yale University School of Medicine, 333 Cedar Street, PO Box 208088, New Haven, CT 06520-8088, USA. harlan.krumholz@yale.edu
Ross
Joseph S
JS
Presler
Amos H
AH
Egilman
David S
DS
D002318:Cardiovascular Diseases / Q000139:chemically induced*; D035881:Compensation and Redress / Q000331:legislation & jurisprudence*; D052246:Cyclooxygenase 2 Inhibitors / Q000009:adverse effects*; D004345:Drug Industry / Q000331:legislation & jurisprudence*; D006801:Humans; D007400:Interprofessional Relations; D007783:Lactones / Q000009:adverse effects*; D012307:Risk Factors; D015871:Scientific Misconduct / Q000331:legislation & jurisprudence; D013450:Sulfones / Q000009:adverse effects*; D013997:Time Factors; D006113:United Kingdom; D014481:United States
D052246:Cyclooxygenase 2 Inhibitors; D007783:Lactones; D013450:Sulfones; C116926:rofecoxib